Gliatilin, 1000 mg/3ml 3 mL 3 pcs

Alzheimer’s disease, Headache, Attention deficit and memory disorders, Stroke sequelae, Aggression and conflict, Mental disorders, Acquired dementia

• ischemic (acute and recovery period) and hemorrhagic stroke (recovery period);
• degenerative and involutionary psycho-organic syndromes and consequences of cerebrovascular failure, such as primary and secondary disorders of mnastic functions, characterized by memory disturbances, confusion, disorientation, decreased motivation, initiative, ability to concentrate;
• changes in the emotional and behavioral sphere: emotional lability, increased irritability, decreased interest, senile pseudo-melancholy;
• multiple dementia.

.

Indications

Acute period of TBI with a predominantly brain stem level of damage (impaired consciousness, coma, focal hemispheric symptoms, symptoms of brain stem damage);
ischemic (acute and recovery period) and hemorrhagic stroke (recovery period);
degenerative and involutional psychoorganic syndromes and consequences of cerebrovascular insufficiency, such as primary and secondary disorders of mnestic functions, characterized by memory impairment, confusion, disorientation, decreased motivation, initiative, and ability to concentrate;
changes in the emotional and behavioral sphere: emotional lability, increased irritability, decreased interest, senile pseudomelancholy;
multi-infarct dementia.

Pharmacological effect

Pharmacological action – neuroprotective.

Active ingredient

Choline alphoscerate

Composition

Solution for intravenous and intramuscular administration
4 ml
choline alfoscerate
1000 mg
inactive ingredient:
water for injections

Contraindications

Hypersensitivity to the components of the drug.

Side Effects

Nausea (as a consequence of dopaminergic activation), in this case the dose of the drug should be reduced.

Overdose

Symptoms: nausea.

Storage conditions

At a temperature not exceeding 25 °C.

Shelf life

5 years.

Manufacturer

Italfarmaco S.p.A., Italy